Mark Keaton
Impact in
-
- Cancer Treatment and Pharmacology
- HER2/EGFR in Cancer Research
- Colorectal Cancer Treatments and Studies
- Pancreatic and Hepatic Oncology Research
-
- Breast Cancer Treatment Studies
Papers in
- Oncology 14
- Cancer Treatment and Pharmacology 10
- HER2/EGFR in Cancer Research 5
- Colorectal Cancer Treatments and Studies 5
- Lung Cancer Research Studies 2
- Pancreatic and Hepatic Oncology Research 1
-
- Lung Cancer Treatments and Mutations 4
- Advanced Breast Cancer Therapies 3
- Co-authors
- Graydon Harker (3 shared papers)Tarek Chidiac (3 shared papers)Thomas M. Cosgriff (3 shared papers)B. Mirtsching (3 shared papers)Myo Min (3 shared papers)Barrett H. Childs (2 shared papers)John D. Hainsworth (3 shared papers)Hagop Youssoufian (1 shared paper)
- Journals
- Journal of Clinical Oncology (7 papers)Clinical Breast Cancer (4 papers)Investigational New Drugs (2 papers)Genes & Diseases (1 paper)Lung Cancer (1 paper)
- Partner nations
- United StatesUnited KingdomChina
In The Last Decade
Mark Keaton
15 papers receiving 235 citations
Peers
Comparison fields: 5 of 37
- Oncology 176
- Cancer Research 43
- Pulmonary and Respiratory Medicine 47
- Biomaterials 20
- Hepatology 6
Countries citing papers authored by Mark Keaton
This map shows the geographic impact of Mark Keaton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Keaton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Keaton more than expected).
Fields of papers citing papers by Mark Keaton
This network shows the impact of papers produced by Mark Keaton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Keaton. The network helps show where Mark Keaton may publish in the future.
Co-authors
The 25 scholars most cited alongside Mark Keaton, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2011 | 58 | |
| 2 | 2011 | 49 | |
| 3 | 2014 | 47 | |
| 4 | 2011 | 25 | |
| 5 | 2011 | 16 | |
| 6 | 2009 | 10 | |
| 7 | 2014 | 9 | |
| 8 | 2017 | 5 | |
| 9 | 2015 | 5 | |
| 10 | 2006 | 4 | |
| 11 | 2008 | 4 | |
| 12 | 2017 | 2 | |
| 13 | 2009 | 2 | |
| 14 | 1990 | 2 | |
| 15 | 2009 | 1 | |
| 16 | 2008 | 0 |
About Mark Keaton
Mark Keaton is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Molecular Biology and Pharmacology, having authored 16 papers that have together received 239 indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (10 papers), HER2/EGFR in Cancer Research (5 papers), Colorectal Cancer Treatments and Studies (5 papers), Lung Cancer Treatments and Mutations (4 papers), Advanced Breast Cancer Therapies (3 papers), Breast Cancer Treatment Studies (3 papers), Lung Cancer Research Studies (2 papers) and Pancreatic and Hepatic Oncology Research (1 paper). The work is most often cited by research in Oncology (176 citations), Cancer Research (43 citations), Pulmonary and Respiratory Medicine (47 citations), Biomaterials (20 citations) and Hepatology (6 citations). Mark Keaton has collaborated with scholars based in United States, United Kingdom and China. Frequent co-authors include Graydon Harker, Tarek Chidiac, Thomas M. Cosgriff, B. Mirtsching, Myo Min, Barrett H. Childs, John D. Hainsworth, Hagop Youssoufian, Eric K. Rowinsky and Heinz‐Josef Lenz. Their work appears in journals such as Journal of Clinical Oncology, Clinical Breast Cancer, Investigational New Drugs, Genes & Diseases and Lung Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.